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ABSTRACT
Isogenic pluripotent stem cells are critical tools for
studying human neurological diseases by allowing
one to study the effects of a mutation in a fixed
genetic background. Of particular interest are the
spectrum of autism disorders, some of which are
monogenic such as Timothy syndrome (TS); oth-
ers are multigenic such as the microdeletion and
microduplication syndromes of the 16p11.2 chro-
mosomal locus. Here, we report engineered human
embryonic stem cell (hESC) lines for modeling these
two disorders using locus-specific endonucleases
to increase the efficiency of homology-directed
repair (HDR). We developed a system to: (1) compu-
tationally identify unique transcription activator-like
effector nuclease (TALEN) binding sites in the
genome using a new software program, TALENSeek,
(2) assemble the TALEN genes by combining golden
gate cloning with modified constructs from the
FLASH protocol, and (3) test the TALEN pairs in
an amplification-based HDR assay that is more
sensitive than the typical non-homologous end
joining assay. We applied these methods to identify,
construct, and test TALENs that were used with
HDR donors in hESCs to generate an isogenic
TS cell line in a scarless manner and to model
the 16p11.2 copy number disorder without modi-
fying genomic loci with high sequence similarity.
INTRODUCTION
Stem cell models provide a robust platform for generating
the cell types of the body and understanding how they are
altered in the context of disease. Human diseases can be
modeled using induced pluripotent stem cells (iPSCs) de-
rived from patients (1). However, genetic variation across
the rest of the patient’s genome confounds the study of a
specific mutation’s effects. Engineering an isogenic muta-
tion into healthy pluripotent stem cells allows the isolated
study of that genotypic variation, holding constant any ef-
fects due to the underlying genetic background. Although
the mutant gene can be introduced at a safe harbor locus
if it is known to have a dominant negative phenotype (2),
targeting the endogenous locus more similarly matches the
genomic context of the disease (3). The challenge of intro-
ducing a pointmutation into the endogenous locus in a scar-
less manner has been accomplished by taking advantage of
a nearby transposon-recognition site (4) or by introducing
a single-stranded oligodeoxynucleotide (ssODN) donor for
homology-directed repair (HDR) (3,5,6).
The genomes of pluripotent systems, such as human em-
bryonic stem cells (hESCs) and iPSCs, are challenging to
modify due to their low transfection efficiency, poor via-
bility during transfection, and low single-cell cloning effi-
ciency (7). Introducing a site-specific double-strand break
(DSB) using a targeted endonuclease (8–13) increases the
rate of HDR by four orders of magnitude (14). When com-
bined with a nuclease, a donor with regions of homology
flanking the cut site allows targeted editing of genomic
DNA. Zinc finger nucleases, transcription activator-like ef-
fector nucleases (TALENs), and clustered regularly inter-
spaced short palindromic repeats (CRISPR)-Cas enzymes
have been used to introduce DSBs for HDR in hESCs and
iPSCs (2–6). As nuclease gene assembly is a small fraction
of the time and effort required to create an engineered hES
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cell line, the ease of CRISPR-Cas gene construction (12,13)
relative to obligate dimeric TALENs (10,11) may not out-
weigh the potential off-target effects of monomeric nucle-
ases (15–18).
Here, we present techniques for the design, assembly,
and testing of site-specific TALENs for genes associ-
ated with autism spectrum disorders (ASDs; CACNA1C
and KCTD13), neuronal development (FOXG1, PAX6,
PVALB, SOX1, and TUBB3), and the Wnt/-catenin sig-
naling pathway (FOXM1 and TMEM88). We used pairs of
TALENs to generate isogenic hESCs to model two known
genetic causes of ASDs. The mutation of Gly406 to Arg
(G406R) in the L-type voltage-sensitive calcium channel
Cav1.2 (CACNA1C) is conserved in patients with Timothy
syndrome (TS), a disorder that affects multiple organs in-
cluding the brain, heart and digits, producing phenotypes
that include autism and long QT (19). This mutation re-
sults in nearly complete loss of voltage-dependent channel
activation, producing sustained inward Ca2+ currents. The
G406R mutation was introduced in a scarless manner to
match the local genetic environment of patients in a fixed
hESC genetic background. KCTD13, the key gene in the
16p11.2 chromosomal locus where copy number variation
(CNV) has been associated with autism-linked phenotypes
(20–23), was disrupted in a manner that reduced gene ex-
pression.
We present techniques to generate isogenic engineered
cell lines, including: (1) identifying unique TALEN-binding
sites to loci of interest using TALENSeek software, (2) as-
sembling the TALEN genes using the golden gate FLASH
(ggFLASH)method, and (3) testing theTALENpairs using
a HDR-dependent single-stranded oligodeoxynucleotide
donor assay (ssODA). The methods used here for genera-
tion of ASDmodels in hESCs can be applied for generation
of isogenic disease models of any monogenic disorder.
MATERIALS AND METHODS
Identifying TALEN-binding sites
TALENSeek was generated as a script in the R program-
ming language (available at http://geschwindlab.neurology.
ucla.edu/protocols) calling the packages biomaRt (24)
and BSgenome (Pages, H. BSgenome: Infrastructure for
Biostrings-based genome data packages. R package ver-
sion 1.30.0). The search for off-target binding was accom-
plished via inexact matching using the matchPDict() func-
tion of the Biostrings package (Pages, H., Aboyoun, P.,
Gentleman, R., DebRoy, S. Biostrings: String objects rep-
resenting biological sequences, and matching algorithms. R
package version 2.32.0). On a desktop computer, identify-
ing TALEN-binding site with TALENSeek typically takes
a fewminutes per gene with the time dependent on the num-
ber of matching off-target sites identified and whether bind-
ing sites are set to match human only or mouse and human
genomes simultaneously: approximately 12 min to identify
one TALEN pair each at the start and end of a gene with
off-target sites identified in the human genomewhen search-
ing only the human genome and approximately 20 min per
gene for a human and mouse genomic search without off-
target site identification when searching for homologous
mouse and human binding sites. In the worst case scenario,
where the program searches iteratively but does not find ho-
mologous sites in human and mouse genomes, the maximal
run time is approximately eight hours. The identification of
TALEN-binding sites is independent of the TALEN gene
assembly; therefore, TALENSeek is compatible with gene
assembly methods using the common TALEN framework
and any set of repeat variable di-residues (RVDs; (10,25)).
TALEN gene assembly by ggFLASH
The golden gate FLASH assembly of TALEN genes
used the FLASH library of tetramer and trimer subunits
(26)––with Asn-Ile, His-Asp, Asn-Asn, and Asn-Gly as
the RVDs for adenosine, cytidine, guanosine, and thymi-
dine, respectively (10)––and a modified set of repeat ar-
ray receiving vectors (AI-CN441, AI-CN442, AI-CN443,
and AI-CN491; Addgene plasmids 62590, 62591, 62593,
and 62594, respectively; Supplementary Methods) con-
taining obligate homodimeric FokI nuclease domains for
golden gate cloning (27–30). The selected target sites from
TALENSeek were entered into FLASHplasmids, a com-
plementary program written in Java (available at http://
geschwindlab.neurology.ucla.edu/protocols) that identified
the necessary components and generated a GenBank for-
matted file for each TALEN. The ggFLASH method and
the FLASHplasmids program can each be extended to in-
clude future subunit reagents containing alternate RVDs
(25).
TheFLASH repeat array subunits were polymerase chain
reaction (PCR)-amplified with primers specific to the lo-
cation of each subunit within the final array (Supplemen-
tary Table S1). Each set of four reactions per TALEN were
combined and purified; approximately 1 g of total puri-
fied products were digested overnight with 1 L of BbsI
(Thermo Scientific; FastDigest BbsI FD1014). The appro-
priate receiving vector was digested with BbsI, treated with
Antarctic phosphatase (New England Biolabs), and stored
at −20◦C for future use.
For the golden gate reaction, the reagents were mixed on
ice: 4 L of purified PCR product pool at approximately
50 ng/L, 1 L of digested vector at 50 ng/L, 5 L of
nuclease-free water, 1.5 L of 10×Gbuffer (Thermo Scien-
tific), 1.5 L of 10 mM ATP, 1 L of BbsI, and 1 L of T4
ligase at 400 U/L (New England Biolabs). The reaction
conditions were: (1) 25 cycles of 37◦C, 3 min and 16◦C, 4
min; (2) 50◦C, 5 min; and (3) 80◦C, 5 min (31). Then, 2.5 L
of the reaction was transformed into chemically competent
DH5 cells (New England Biolabs) and placed onto plates
with carbenicillin, Xgal, and IPTG. The plasmids were vali-
dated by insert check PCR and sequencing (Supplementary
Table S1).
TALEN activity by ssODA and CEL-I
For ssODA, K562 cells (0.5 or 1.0 × 106; ATCC CCL-243)
were electroporated (Lonza Amaxa 4D instrument with SF
cell line kit) with 4 g of each TALEN plasmid (Supple-
mentary Table S2) and 0.3 nmol of the 120 nt ssODNHDR
donor (Supplementary Table S3); the reagent amounts were
consistent in the TALEN pair or ssODN donor-only con-
trols. After 48–72 h at 37◦C, genomic DNA was harvested
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for junction PCR (QuickExtract; Epicentre orGentra Pure-
gene Cell; Qiagen). Each ssODN contained ataacttcgtatag-
catacattatacgaagttatagatct, encoding a loxP recognition site
and a BglII restriction site, flanked by 40 nt of homology on
each side of the predicted cut site (32).
For the CEL-I assay, K562 cells (1× 106) were electropo-
rated with 5g of each TALENplasmid. The untransfected
control is shown only when background CEL-I activity was
observed. After 48–72 h, genomic DNA was harvested for
PCR. For each target, the single band product was puri-
fied, denatured, re-annealed, and incubated with Surveyor
Nuclease S (Transgenomic). The reactions were quantified
by capillary electrophoresis (QIAxcel Advanced, high reso-
lution kit, OM500 method; Qiagen).
Timothy syndrome mutation in hESCs
H1 hESCs (WA01; WiCell) were maintained in mTeSR1
(StemCell Technologies) onMatrigel (BD) unless otherwise
noted. At p39, cells were treated with 1 M thiazovivin
(StemRD) one day before electroporation (Neon; Invit-
rogen; resuspension buffer R; 100 L electroporation tip;
1050 V, 30 ms pulse width, 2 pulses; 1 × 106 cells) as a
single-cell suspension (StemPro Accutase, Life Technolo-
gies) with 4 g of each TALEN plasmid and 0.3 nmol
of the ssODN. A donor-only control included 0.6 nmol
of ssODN with 1 × 106 cells. The ssODN HDR donor
sequence was TCATAGGGTCATTTTTTGTACTTAAC
TTGGTTCTCGGTGTCTTGTCTaGGTAAGCAGGAC
CAAGGAAAAAGGTCTTGATTTTTCCATT, where
the point mutation is in lowercase and the underlined
nucleotides introduced an insertion-specific primer binding
site while retaining exon coding identity.
The cells were treated with 2 M thiazovivin for 24 h fol-
lowing electroporation. A preliminary test by 5′ junction
PCR one week after electroporation confirmed the targeted
integration of the mutation in the cells that received the
TALENs and donor, but not the ssODN-only. At that time,
cells were plated at 500 cells/well into each well of 6 × 96-
well plates with 2 M thiazovivin. Ten days later, the cells
were treated with StemPro Accutase for 2 min at 37◦C, one
half of the cells was replica-plated onto new 96-well plates
and genomic DNA was harvested (QuickExtract) from the
remaining cells in each well.
In the first round of PCR screening, DNA was com-
bined from each well in a single row. These 48 total sam-
ples were analyzed by quantitative PCR (qPCR; LightCy-
cler 480; Roche) in a single 96-well PCR plate for the 5′ and
3′ junctions using SYBR green I Taq mix (Roche). The four
most promising rows were identified as those with the great-
est increase in fluorescence, the correct product Tm, and the
presence of a single product band at the correct size band
by electrophoresis for at least one junction reaction. In the
second round, each well from the selected rows was tested
individually; the three best wells were combined for single-
cell cloning.
The resulting clones at p46, two months after transfec-
tion, were tested by junction PCR with primers for both
the desired mutation and the wild-type background. The
absence of a wild-type product band, but the presence
of the mutation, indicated that the clone was homozy-
gous for the desired mutation. The identity of the clone
was confirmed by locus amplification, blunt cloning (Zero
Blunt TOPO, Life Technologies), and sequencing the in-
sert of six bacterial colonies; all six showed the desired
mutation, confirming the identification of the homozygous
CACNA1CG406R/G406R cell line. This linewas namedAI07e-
Timothy (33) and has a normal karyotype (Cell LineGenet-
ics, Supplementary Figure S1). Flow cytometry of pluripo-
tency markers (BD Pharmingen: NANOG, 560483; OCT4,
560794; SOX2, 560294) demonstrated that the clone was
similar to the unmodified H1 hESC (Supplementary Figure
S2).
KCTD13 disruption in hESCs
H1 cells at p36 were treated with 1 M thiazovivin one
day prior to electroporation (3 × 106 cells; conditions
as per TS hESC) as single cells (Accutase) with 0.5 g
of each TALEN plasmid and 2 g of the HDR donor
plasmid AI-CN590 (Addgene plasmid 62596; Supplemen-
tary Methods). Cells were plated into a single well of a
six-well plate with CF-1 MEFs (GlobalStem), hES media
(DMEMF12 with 20% KSR; Life Technologies), and 2
M thiazovivin. After five days in hES media, cells were
passaged onto DR4 MEFs (GlobalStem) and maintained
for three days prior to a five day treatment with 1 g/ml
puromycin (Life Technologies). Individual colonies were
picked within the following three days. At p43, five weeks
after transfection, transgene integration was assayed by
PCR (Supplementary Table S1). The heterozygous and ho-
mozygous clones, AI09e-KCTD13a and AI10e-KCTD13b
respectively, have normal karyotypes (Cell Line Genetics,
Supplementary Figure S3) and the pluripotency marker
expression pattern of hESCs (Supplementary Figure S4).
Following reverse transcription of RNA from modified
and parental hESCs, the cDNA was assayed by qPCR
with primers for KCTD13 (CTGCCGGAGAGTACGA-
GAGA, GGACAGCGTCTCCCTTTTT) and the refer-
ence HSP90AB1 (CCTCACTAATGACTGGGAAGAC,
CAACTCATCACAGCTGTCCATGA).
Off-target analyses in engineered hESCs
Human genomic sequences similar to the desired TALEN-
binding sites used in generating the KCTD13 disruption
and TS mutation cell lines were identified computation-
ally (Supplementary Table S4). The search reported loci
where two TALENs, either as heterodimeric or homod-
imeric pairs, beginning with thymine and spaced 12–20 bp
apart might bind and modify the genome. As the Asn-
Asn RVD was used for targeting guanosine, the presence
of adenosine instead of guanosine at the same position in
the binding site was not counted as a mismatch.
RESULTS
TALEN-binding sites identified
The first procedure in generating isogenic cell lines is the
identification of unique TALEN-binding sites. Such sites
must satisfy a set of rules influencing their binding poten-
tial and specificity (26). For generation of TALEN-binding
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sites anywhere in the human genome (34–37), we wrote a
software program in the R programming language called
TALENSeek. TALENSeek finds TALENpair binding sites
near a genomic locus of interest or the 5′ and 3′ ends of
a user-specified gene in the genome and also generates ho-
mology sequences used for HDR donor construction. The
program inputs are the HUGO gene name of interest (www.
genenames.org), the length of the TALEN-binding sites and
the spacer separating them, the number of mismatches al-
lowed when searching for off-target binding sites in the
genome, and the desired length of homology surrounding
the TALEN-induced DSB. In addition, the program allows
for discovery of unique homologous TALEN-binding sites
that are conserved in both human and mouse genomes.
TALENSeek first creates the super-isoform, the furthest
5′ and 3′ length across all isoforms defined in ENSEMBL,
for the specified gene (Figure 1a). Near the transcriptional
start and stop sites, an acceptable TALEN-binding site pair
is sought where the pairs are separated by 15–30 bp and
each 14–19 bp binding site begins with a T. The program
searches iteratively into the gene until an acceptable site
is found (Figure 1b and c). This site is then searched for
uniqueness in the genome, allowing for a number of user-
defined mismatches. If a homologous sequence in human
and mouse is specified, the binding site identified in the hu-
man genome is tested to be within 250 bp of the start or
end site of that same gene in the mouse genome (Figure 1d).
The user has the option to test if the TALEN-binding site is
unique in each genome. The output includes a .bed file for
visualization in the UCSC genome browser (38) that identi-
fies the individual TALEN-binding sites in the human and
mouse genomes for each specified target (Figure 1e).
TALENSeek has some unique features in comparison to
other TALEN-binding site detection algorithms currently
available (Supplementary Table S5). Notably, TALENSeek
allows for binding site detection near a gene of interest
by simply entering the gene symbol rather than finding
and copying each sequence of interest. In addition, TAL-
ENSeek iteratively searches for binding sites which do not
have off-target sites (with the user inputted number of mis-
matches). Other programs with off-target search availabil-
ity (34,36,39–41) all require first running a TALEN iden-
tification program prior to the separate off-target search.
Lastly, TALENSeek offers the user the ability to design
a TALEN that homologously targets a gene of interest in
both human and mouse. This unique feature can allow the
user to save both reagent costs and time by limiting the
number of TALENs produced as well as likely having a
more consistent binding specificity for cross-species experi-
ments. TALENSeek does not implement an empirically de-
termined binding affinity algorithm as previous algorithms
(29) were not supported by subsequent literature (26). A re-
cent binding site algorithm provides a large data set to em-
pirically determine binding site scores (42). This is very en-
couraging and we would urge users to utilize both tools for
their specific advantages.
ggFLASH assembly of TALEN genes
The assembly of a TALEN-coding gene is non-trivial as
each TALEN typically contains 12–20 repeats of 34 amino
acids that are conserved in 32 positions per repeat (10).
Of the numerous methods to construct TALEN genes
(10,26,28–30,37,43,44), including high-throughput meth-
ods that use liquid handling robotics (37,44), the FLASH
assembly method (26) is attractive in its speed, robust as-
sembly, and library of component plasmids. The library
contains plasmids encoding up to four TALEN repeat ar-
ray subunits, but the FLASH method of TALEN assembly
requires microgram quantities of plasmids. The ggFLASH
assembly method combines the FLASH plasmid library
with the ligation specificity and small amounts of materi-
als needed in golden gate cloning (Figure 2a; (27–30)).
Instead of large-scale preparations of the plasmid li-
brary members, the desired plasmids are PCR-amplified
with primers specific to that subunit’s position in the ar-
ray. For example, targeting 18 bp requires assembly of 16.5
repeats using four PCR-amplified tetramers and a vector
encoding the initial thymine recognition element and final
half-repeat. One-pot golden gate cloning is most efficient
when a single restriction enzyme can be used to digest all
of the components. The four receiving vectors shared by the
REAL and FLASHmethods use BsmBI restriction sites for
insertion of the repeat array (43); however, this site is present
within the FLASH tetramer repeat subunits. To create a sys-
tem compatible with golden gate cloning while continuing
to use the FLASH plasmid library, the four array receiv-
ing vectors were modified by removing the two BbsI sites
and replacing the BsmBI array insertion site with a lacZ
expression cassette flanked by two new BbsI sites. Follow-
ing golden gate assembly and transformation, twelve white
colonies are typically screened by PCR; constructs with an
insert of the appropriate size are sequenced, and 60% of the
sequenced clones are correct. At least one clone is correct
in >90% of the twelve picked colonies per construct; this
efficiency is similar to the FLASH protocol (26). Errors in-
troduced by PCR amplification of the 0.3–0.4 kb subunits
were present in <10% of sequenced clones.
The ggFLASH method was used to assemble TALEN
constructs to ten loci in the human genome using either four
tetramer repeats or three such repeats and a trimer to target
18 or 17 bp, respectively (Figure 2a). These loci were iden-
tified by TALENSeek to nine genes associated with neu-
ral disorders (CACNA1C and KCTD13) or development
(FOXG1, FOXM1, PAX6, PVALB, SOX1, TMEM88, and
TUBB3). Formodeling TS, the TALENpairs target Gly406
of CACNA1C (CACNA1C-Gly406; (19)); for the 16p11.2
microdeletion and microduplication syndrome the target is
the N-terminus of the key gene (KCTD13-N).
Homology-directed repair assay for nuclease activity
A rapid assay to qualitatively assess HDR activity is nec-
essary prior to spending weeks to months generating a
transgenic hESC line (3,5,6). Following design and assem-
bly of the TALEN pairs, the endonucleases were tested in
K562 cells due to their high transfection efficiency prior to
genome engineering of hESCs. Engineered nucleases are of-
ten tested by a non-homologous end joining (NHEJ) assay
with the CEL-I endonuclease (45) or with a frame-shifted
nonfunctional green fluorescent protein either integrated
(9) or expressed episomally (46). Assessment of HDR activ-
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Figure 1. Description of TALENSeek, an automated TALEN-binding site detection algorithm. (a) Automated annotation of genomic regions is used to
identify start and end sites of a gene of interest using the farthest protein coding regions across all isoforms (a super-isoform). (b) Potential TALEN-binding
sites are identified. (c) The sites are evaluated for uniqueness across the genome. (d) If a binding site is not unique, the search continues further into the gene
and the algorithm iterates from step (b). (e) The output .bed file allows visualization of the TALEN-binding sites in the UCSC genome browser, shown
with human genome build GRCh37 (hg19).
ity has been done by detecting a restriction fragment length
polymorphism (RFLP) following introduction of a restric-
tion endonuclease recognition site (32), but this requires in-
tegration at sufficient levels to detect digestion products. A
sensitiveHDRassaywas desired that would confirm the tar-
geted integration of a homologous donor.
The ssODA is an amplification-based assay that only pro-
duces a junction PCR product if an exogenous sequence
is integrated in the target site. Cells are transfected with a
TALEN pair and a ssODN donor containing 40 nt of ex-
ogenous sequence flanked on each end by 40 nt of homol-
ogy (Figure 2b; (32)). The exogenous sequence is used as a
primer-binding site for junction PCR that produces a prod-
uct only upon integration of the ssODN (Figure 2c).
In K562, the ssODA both corroborated and was more
sensitive than the CEL-I assay and the ssODA was insensi-
tive to background polymorphisms (Figure 2d and Supple-
mentary Figures S5–S8). At three loci in K562 cells, weaker
HDR activity of ssODN donors was observed in the ab-
sence of engineered nucleases (Supplementary Figures S5a,
S6a, S7b). Such background activity has been reported in
mammalian cells previously (47), but was not observed dur-
ing the preparation of theTS stem cell line or in similarwork
in iPSCs (6). Of the ten TALEN pairs designed by TAL-
ENSeek and assembled by ggFLASH, 90% (9/10) were ac-
tive by ssODA but only 29% (2/7) were conclusively active
by CEL-I. The inactivity of the FOXG1-N TALEN pair,
which had the highest guanosine content (44%) of all tar-
geted TALEN-binding sites, could be due to the use of the
Asn-Asn RVD (10), the local chromatin structure (48), or
the DNA methylation (37,48) of this gene associated with
telencephalon development (49) in the bone-marrow de-
e65 Nucleic Acids Research, 2015, Vol. 43, No. 10 PAGE 6 OF 9
Figure 2. TALEN gene assembly and HDR activity assay. (a) TALEN assembly by ggFLASH. The PCR products for the four subunits include pairs of
BbsI recognition sequences (bold) and overhangs (underlined). The repeat array receiving vectors each contain a LacZ expression cassette flanked by BbsI
sites. (b) In the ssODA, a LoxP sequence and BglII recognition site (bold) are introduced with a ssODN donor. Schematics in (a) and (b) are not to scale.
(c) Integration of a ssODN donor into the KCTD13 N-terminus of K562 cells required the presence of the appropriate TALEN pair. An asterisk denotes
the desired product band. (d) CEL-I activity for TALENs that were active by ssODA in K562 cells.
rivedK562 cell line. The CACNA1C-Gly406 andKCTD13-
N TALEN pairs active by ssODA were each used with an
appropriate homologous donor to generate hESCs tomodel
ASDs.
hESC models of ASDs
The CACNA1C G406R mutation that is conserved in pa-
tients with TS was introduced into the non-disease H1
hESC background to generate an isogenic cell line. To gen-
erate this mutation in a scarless manner, hESCs cells were
transfected with a TALEN pair and an 88 nt ssODN. This
ssODN included 40 nt of homology on both the 5′ and
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Figure 3. Engineered H1 hESCs for modeling human disease. (a) Aligned sequencing chromatograms showing the CACNA1C G406R mutation with the
incorporation of the desired mutations (red nucleotides) from the ssODN. The first two codons of residue 406 are underlined. (b) The disruption cassette
that was introduced immediately 3′ of the start codon of KCTD13 by HDR. (c) Colony of engineered KCTD13 heterozygous clone; scale bar 500 m. (d)
KCTD13 gene expression in the homozygous, dark grey, and heterozygous, light grey, KCTD13 disruption cell lines normalized to the expression in the
parental H1 hESC (n = 3, error bars represent 1 standard deviation).
3′ ends of a central region including the G to A muta-
tion encoding Arg406 and six silent mutations to create a
unique primer-binding site (Figure 3a). The splice junction
and the coding sequence of other residues in exon 8 were
retained. Following a round of enrichment and single-cell
cloning, the targeted loci of six selected clones were ana-
lyzed by sequencing blunt-cloned PCR products. One ho-
mozygous clone (CACNA1CG406R/G406R) with targeted in-
tegration was identified.
Isogenic disease models will be useful tools for studying
ASDs of both single gene origin, such as TS, and larger
genotypes such as the CNVs of the 29 gene region of chro-
mosome 16p11.2. Patients with 16p11.2 microdeletion or
microduplication have a range of neurocognitive disorders
and macroencephaly or microencephaly, respectively (50).
Recent work has demonstrated that KCTD13, a single gene
in this locus, may be the causative gene for the 16p11.2 dis-
orders; in zebrafish, the CNV of this gene matched the ob-
served neuroanatomical phenotypes of the regional CNV
(20).
To disrupt the expression of KCTD13, an homologous
donor plasmid was designed to insert stop codons in all
three frames and a selection and screening cassette express-
ing puromycin resistance and the cerulean fluorescent pro-
tein (51) under the control of the constitutive hEF1 pro-
moter (Figure 3b). The transgenes were flanked by 470 bp
of homology on each side of the start codon. H1 hESCs
were transfected with the KCTD13-N TALENs targeting
the 5′ terminus of the coding region and the HDR plasmid.
Following puromycin selection, twelve fluorescent colonies
(Figure 3c) were selected, expanded, and analyzed by PCR
for targeted integration. Eight colonies were heterozygous
for the targeted integration of the transgenes, one colony
was homozygous and three lacked the transgenes at the
desired locus. In undifferentiated hESCs, the heterozygous
and homozygous clones with the inserted disruption ele-
ments each had the phenotype of healthy hESCs (Supple-
mentary Figures S2 and S4) with a decreased expression of
KCTD13 relative to unmodified H1 cells (Figure 3d).
In addition to the desired HDR activity of the TALENs
and the plasmid or ssODN donor, the exogenous endonu-
cleases used to introduce the site-specific DSB could also
modify the genome by NHEJ activity at loci with simi-
lar sequences. The most similar loci to the KCTD13 and
CACNA1C TALEN-binding sites were nine loci with four
or five mismatches and seven loci with six or seven mis-
matches, respectively (Supplementary Table S4). Fifteen of
these sixteen sites were amplified by PCR and sequenced in
unmodified H1 and the corresponding engineered hESCs.
Nomodifications were identified at these loci in these clones
relative to H1.
DISCUSSION
Isogenic cell lines with a fixed genetic background are nec-
essary for the study of human disease (3). In addition to
generating isogenic hESCs for the study of two autism
spectrum disorders, we report methods to identify unique
TALEN-binding sites in the human genome using TAL-
ENSeek software, construct the genes using golden gate
FLASH, and test the nuclease pairs with an amplification-
based homology-directed repair assay at the loci of inter-
est. TALENSeek, which can be run in a timely manner on
a desktop computer, identifies TALEN-binding sites in the
human genome, has the ability to find unique homologous
binding sites in the human andmouse genomes, and is mod-
ifiable to find TALEN-binding sites in any species with an
available complete genome sequence.
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There are several advantages of the golden gate FLASH
TALEN assembly method that produces correct TALEN
genes at the same efficiency as the original FLASHmethod
(26). Firstly, only nanogram quantities of PCR products
are required instead of microgram quantities of plasmids;
artifacts from amplification of the trimer or tetramer sub-
units are observed in <10% of sequenced clones. The lacZ
cassette in each receiving vector enables targeted investiga-
tions of plasmids that have an inserted array. Finally, the
unique position-specific overhangs necessary for the golden
gate cloning reaction provide internal primer-binding sites
for sequencing of the repeat array, obviating the need for
long sequencing reads from outside of the array.
This represents a bioinformatic, cloning, and testing set
of tools to design, assemble, and assess the homology-
directed repair activity of any TALEN pair. We utilized
these tools and methods to generate hESC lines that dis-
rupt the expression ofKCTD13 and scarlessly introduce the
TS point mutation without modifying the genome at simi-
lar loci. These reagents and techniques could be applied to
correct the Arg406mutation in iPSCs from patients with TS
(52), create a KCTD13 reporter cell line to monitor intra-
cellular protein levels in live cells, or create isogenic cell lines
for studying other human diseases.
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Supplementary Data are available at NAR Online.
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